Rabdomyolyse bij de combinatie statine + macrolide

S. R. Postma; J. I. Van Der Spoel; P. H M Egbers; E. J F Franssen; P. H J Van Der Voort

Rabdomyolyse bij de combinatie statine + macrolide

Translated title of the contribution: Rhabdomyolysis by combined treatment with statin and macrolide antibiotic

S. R. Postma, J. I. Van Der Spoel, P. H M Egbers, E. J F Franssen, P. H J Van Der Voort^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Statins are frequently used as lipid-lowering drugs. Their pleiotropy also makes them beneficial for patients who develop sepsis. As a consequence, intensivists are inclined to continue statin therapy in patients with sepsis. We describe two intensive care patients who developed rhabdomyoiysis during combined treatment with simvastatin and erythromycin. Erythromycin, as an inhibitor of cytochrome P450, increases the risk of statin-related rhabdomyoiysis. The combination of macrolide antibiotics and statins should therefore be avoided in intensive care.

Original language	Dutch
Pages (from-to)	45-47
Number of pages	3
Journal	Pharmaceutisch Weekblad
Volume	142
Issue number	11
Publication status	Published - 16 Mar 2007

Access to Document

Link to publication in Scopus

Cite this

Postma, S. R., Van Der Spoel, J. I., Egbers, P. H. M., Franssen, E. J. F., & Van Der Voort, P. H. J. (2007). Rabdomyolyse bij de combinatie statine + macrolide. Pharmaceutisch Weekblad, 142(11), 45-47.

@article{11d2438861504d3aaac2a90b38f74ce3,

title = "Rabdomyolyse bij de combinatie statine + macrolide",

abstract = "Statins are frequently used as lipid-lowering drugs. Their pleiotropy also makes them beneficial for patients who develop sepsis. As a consequence, intensivists are inclined to continue statin therapy in patients with sepsis. We describe two intensive care patients who developed rhabdomyoiysis during combined treatment with simvastatin and erythromycin. Erythromycin, as an inhibitor of cytochrome P450, increases the risk of statin-related rhabdomyoiysis. The combination of macrolide antibiotics and statins should therefore be avoided in intensive care.",

author = "Postma, {S. R.} and {Van Der Spoel}, {J. I.} and Egbers, {P. H M} and Franssen, {E. J F} and {Van Der Voort}, {P. H J}",

year = "2007",

month = "3",

day = "16",

language = "Dutch",

volume = "142",

pages = "45--47",

journal = "Pharmaceutisch Weekblad",

issn = "0031-6911",

publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",

number = "11",

}

TY - JOUR

T1 - Rabdomyolyse bij de combinatie statine + macrolide

AU - Postma, S. R.

AU - Van Der Spoel, J. I.

AU - Egbers, P. H M

AU - Franssen, E. J F

AU - Van Der Voort, P. H J

PY - 2007/3/16

Y1 - 2007/3/16

N2 - Statins are frequently used as lipid-lowering drugs. Their pleiotropy also makes them beneficial for patients who develop sepsis. As a consequence, intensivists are inclined to continue statin therapy in patients with sepsis. We describe two intensive care patients who developed rhabdomyoiysis during combined treatment with simvastatin and erythromycin. Erythromycin, as an inhibitor of cytochrome P450, increases the risk of statin-related rhabdomyoiysis. The combination of macrolide antibiotics and statins should therefore be avoided in intensive care.

AB - Statins are frequently used as lipid-lowering drugs. Their pleiotropy also makes them beneficial for patients who develop sepsis. As a consequence, intensivists are inclined to continue statin therapy in patients with sepsis. We describe two intensive care patients who developed rhabdomyoiysis during combined treatment with simvastatin and erythromycin. Erythromycin, as an inhibitor of cytochrome P450, increases the risk of statin-related rhabdomyoiysis. The combination of macrolide antibiotics and statins should therefore be avoided in intensive care.

UR - http://www.scopus.com/inward/record.url?scp=34147207387&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34147207387

VL - 142

SP - 45

EP - 47

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

SN - 0031-6911

IS - 11

ER -